IC
SLN

Ikarian Capital’s Silence Therapeutics SLN Stock Holding History

Ikarian Capital’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.73M Hold
865,784
– – 0.14% 104
2025
Q4 		$1.73M Sell
865,784
-35,000
-4% -$224K 0.14% 107
2025
Q3 		$1.31M Buy
900,784
+27,216
+3% +$151K 0.13% 114
2025
Q2 		$1.4M Buy
+873,568
New +$3.75M 0.27% 74
2024
Q4 		– Sell
-587,343
Closed -$3.37M – 201
2024
Q3 		$3.37M Buy
587,343
+80,678
+16% +$1.5M 0.47% 59
2024
Q2 		$3.29M Buy
+506,665
New +$10.8M 0.57% 40

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Ikarian Capital's SLN Position: Q1 2026 in Review

Ikarian Capital held its Silence Therapeutics (SLN) position steady in Q1 2026 at 865,784 shares worth $1.73M. The position accounts for 0.14% of the portfolio, ranked #104.

Ikarian Capital first reported a position in SLN in Q2 2024 and has held it in 6 quarters since. The position peaked at $3.37M in Q3 2024. 56 funds tracked by Wall St. Rank hold SLN as of Q1 2026.

  • Ikarian Capital held 865,784 shares of Silence Therapeutics worth $1.73M as of Q1 2026.
  • Ikarian Capital left its Silence Therapeutics share count unchanged in Q1 2026.
  • Silence Therapeutics made up 0.14% of Ikarian Capital's portfolio in Q1 2026, its #104 holding.
  • Ikarian Capital first reported a position in Silence Therapeutics in Q2 2024 and has held it in 6 quarters since.
  • Ikarian Capital's Silence Therapeutics position peaked at $3.37M in Q3 2024.
  • 56 funds tracked by Wall St. Rank held Silence Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.